Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)

Conference Proceedings

P Schmid, S Kuemmel, D Loirat, P Savas, E Espinosa, V Boni, A Italiano, S White, S Singel, N Withana, A Mani, S Li, A Harris, M Wongchenko, M Sablin

GEBURTSHILFE UND FRAUENHEILKUNDE | GEORG THIEME VERLAG KG | Published : 2020